LifeSci Capital Believes CymaBay Therapeutics (CBAY) Still Has Room to Grow
In a report released yesterday, Patrick Dolezal from LifeSci Capital maintained a Buy rating on CymaBay Therapeutics (CBAY), with a price target of $12.00. The company’s shares closed last Thursday at $8.50, close to its 52-week high of $9.06.
According to TipRanks.com, Dolezal is a 5-star analyst with an average return of 32.1% and a 55.3% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Rocket Pharmaceuticals, and Oyster Point Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CymaBay Therapeutics with a $12.29 average price target, which is a 46.8% upside from current levels. In a report issued on November 2, B.Riley Financial also reiterated a Buy rating on the stock with a $13.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.06 and a one-year low of $1.21. Currently, CymaBay Therapeutics has an average volume of 1.83M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.